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Objective: This prospective, randomized, single-center, open-label pilot study evaluated the safety and efficacy in carotid
surgery of a single intraoperative bolus of body weight–adjusted enoxaparin compared with unfractionated heparin.
Methods: Symptomatic and asymptomatic patients with high-grade internal carotid artery stenosis were included. The
primary objective was to evaluate perioperative efficacy (incidence of thromboembolic ischemic stroke). The secondary
objective was to evaluate safety, including avoidance of hematoma at the site of surgery, gastrointestinal bleeding, rate of
blood transfusions, and occurrence of heparin-induced thrombocytopenia.
Results: From July 2005 to June 2006, 338 consecutive patients undergoing carotid endarterectomy were enrolled; of
these, 115 patients did not fulfill inclusion criteria, and 63 patients refused to participate. The remaining 160 patients
were assigned in a 3:1 randomization to receive enoxaparin (0.5 mg/kg) or unfractionated heparin (5000 IU)
intraoperatively as an intravenous bolus (120 and 40 patients, respectively). The mean patient age was 70.3 years (range,
43.3-94.7 years), and 54 were women. Internal carotid artery stenosis was asymptomatic in 55% and symptomatic in 45%.
The difference in baseline characteristics between these groups was not significant. The rate of cerebral embolic events was
0.8% in the enoxaparin group (n  1) and 2.5% in the unfractionated heparin group (n  1). The rate of severe bleeding
complications was 1.7% in the enoxaparin group (n  2) and 5% in the unfractionated heparin group (n  2; P > .05).
No case of heparin-induced thrombocytopenia was observed.
Conclusion: This pilot study found no difference between enoxaparin and unfractionated heparin during carotid
endarterectomy in perioperative bleeding or embolic events. A large multicenter trial seems to be warranted. ( J Vasc Surg
2008;47:537-42.)Anticoagulation is an elementary therapeutic modality
in vascular surgery. The first anticoagulant medication used
intraoperatively was unfractionated heparin (UFH),1 a sub-
stance that has been almost universally applied until re-
cently. Unfractionated heparin is used either as a standard
intravenous bolus before arterial cross-clamping, usually
5000 IU,2-5 or as a body weight–adjusted dose. Although
UFH is an effective antithrombotic agent, the anticoagu-
lant response it produces in patients is highly variable and
unpredictable.6 Thus, even body weight–adjusted applica-
tion does not always yield the desired target anticoagulation.
In contrast, low-molecular-weight heparins (LMWHs) seem
to be superior, at least during percutaneous coronary interven-
tions.7
Evidence for the beneficial effects of LMWH compared
with UFH in vascular surgery is sparse. One prospective,
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demonstrated that patients receiving the LMWH enoxapa-
rin had a similar occlusion rate of the reconstructed arterial
bed yet statistically significant less blood loss compared
with an UFH group.2 However, carotid endarterectomy
was expressively excluded from the study.
Efficacy of anticoagulation during and after carotid
endarterectomy is crucial because the brain is much less
tolerant to embolic events than other tissues. Safety, on the
other hand, is vital, because bleeding may result in postop-
erative morbidity and in some cases in fatal complications.
The present study was conducted as a pilot trial (before
a planned randomized multicenter study) to estimate the
efficacy and safety of a single intraoperative intravenous
bolus of 0.5-mg/kg body weight–adjusted enoxaparin
compared with 5000 IU of UFH in carotid surgery. This
pilot trial was necessary because no reliable data on antico-
agulation with LMWH in carotid surgery existed thus far.
MATERIAL AND METHODS
This pilot study was a prospective, randomized, single-
center, open-label evaluation of the safety and efficacy of
body weight–adjusted enoxaparin compared with a fixed
dose of UFH in carotid surgery. The primary study objec-
tive was to evaluate the efficacy of UFH, measured as the
incidence of thromboembolic ischemic events during sur-
gery and at 30 days of follow-up. The secondary objective
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ative and postoperative bleeding complications (hematoma
at the site of surgery indicating surgical revision, gastroin-
testinal bleeding, and the rate of blood transfusion), the
occurrence of heparin-induced thrombocytopenia (HIT),
and death.
Patient inclusion criteria. Symptomatic and asymp-
tomatic patients with internal carotid artery (ICA) stenosis
70% according to North American Symptomatic Carotid
Endarterectomy Trial (NASCET) criteria 8 were enrolled in
the study. Internal carotid artery (ICA) stenosis was diag-
nosed by magnetic resonance angiography (MRA) and
duplex ultrasound (DUS) imaging in all patients. Grading
of ICA stenosis by DUS was performed according to pre-
viously published criteria measuring peak systolic velocity
(PVS)9,10:
● PSVs of 150 to 249 mm/s within the ICA and a ratio
of PSV of the ICA and common carotid artery (CCA)
of 2.0 to 3.9 were quantified as 50% to 69% stenosis;
● PSVs 250 mm/s within the ICA and a ratio of PSV
of the ICA and CCA of 4 were quantified as 70% to
99% stenosis.
All patients underwent preoperative and postoperative
neurologic assessment and were scored according to the
National Institute of Health Stroke Score (NIHSS).11 Pa-
tients were assigned in a 3:1 randomization to receive either
enoxaparin (0.5 mg/kg) or UFH (5000 IU) intraopera-
tively as an intravenous bolus (120 and 40 patients, respec-
tively). The study was approved by the local ethics commit-
tee (EK 04-180-0105; EudraCT number: 2004-004762)
and performed in accordance with the Declaration of Hel-
sinki. All patients gave written informed consent.
Patient exclusion criteria. Patients with a recent dis-
abling stroke ipsilateral or contralateral, or both, to the side
scheduled for surgery, patients with a pacemaker or im-
planted cardioverter/defibrillator, patients not tolerating
locoregional anesthesia, and patients with uncontrolled
arterial hypertension (blood pressure 200 mm Hg) at two
successive readings were not included in the study. Also,
patients with active bleeding disorders due to acquired or
inherited coagulopathy, platelet counts 100 109/L or
400 109/L, recent thrombolytic therapy of any vascu-
lar bed (2 weeks before surgery) or patients receiving dual
antiplatelet therapy, clopidogrel monotherapy, not tolerat-
ing aspirin or taking oral anticoagulation were not consid-
ered as candidates to participate in the study. Patients with
a documented episode of HIT or thrombosis, or both, and
anemia (hemoglobin  10 g/mL) were also excluded from
the study.
Surgical procedure and anticoagulation. The stan-
dard surgical technique for all patients was eversion endar-
terectomy. All patients were anesthetized by a C2-C3 cer-
vical block using a 1% lidocaine suspension. After effective
analgesia, a horizontal skin incision parallel to the mandi-
ble, using a skin crease, was performed. Five to 10 minutes
before the ICA was cross-clamped, anticoagulation was
performed according to the randomization list by either asingle, weight-adjusted intravenous bolus of enoxaparin
(0.5 mg/kg body weight; Sanofi-Aventis, Vienna, Austria)
or UFH (5000 IU; Baxter Healthcare, Vienna, Austria).
Intraoperative completion angiography was done in all
patients after endarterectomy and completion of the anas-
tomosis. After meticulous hemostasis, a 12-Charriere suc-
tion drainage was placed at the anastomosis, and skin
closure was completed by an intracutaneous, nonabsorb-
able suture. Only surgeons having the experience of 200
carotid endarterectomies during the last 5 years, and 50
during the year preceding the trial, were performing end-
arterectomies in this study.
Patients in both groups received 40 mg daily of enox-
aparin subcutaneously on the days 1 to 3 after surgery;
aspirin (oral 100 mg acetylsalicylic acid per day) was con-
tinued in all patients on the morning after surgery.
Blood collection and laboratory analyses. Blood
was drawn before and after operation by venipuncture of
the antecubital vein and collected in standard serum and
K3-ethylenediaminetetraacetic acid (EDTA) tubes (Vacu-
ette EDTA Tubes, Greiner Bio-One, Kremsmünster, Aus-
tria). Analysis of levels of total cholesterol, high-density
lipoprotein cholesterol, triglycerides, and serum creatinine
was performed on a Hitachi 917 analyzer (Roche Diagnos-
tics, Mannheim, Germany). Hemoglobin A1c in K3-EDTA
whole blood was analyzed on a Cobas Integra 700 analyzer
(Roche Diagnostics, Basel, Switzerland). Routine hematol-
ogy and chemistry analyses were performed 2 hours after
venipuncture.
For intraoperative antifactor Xa measurements, blood
was drawn from an indwelling catheter in the radial artery
immediately before UFH/enoxaparin administration, and
at 15, 30, and 45 minutes after heparinization. Blood was
collected into a tube containing 3.2% trisodium citrate
(Vacuette Tube, Greiner Bio-One), which was used to
determine the activated partial thromboplastin time
(aPTT) and antifactor Xa activity2 hours after venipunc-
ture. The aPTT was measured on a Sysmex CA7000 coag-
ulation analyzer (Sysmex-Toa, Kobe, Japan) with Actin FS
aPTT reagent supplied by Dade-Behring (Dade-Behring,
Marburg, Germany). Levels of UFH- and enoxaparin-
dependent antifactor Xa activity in plasma were measured
with a commercial chromogenic assay (Biophen Heparin 6,
Hyphen Biomed, Neuville-sur-Oise, France). The antifac-
tor Xa activity assay was calibrated with either UFH or
LMWH calibrators supplied by the manufacturer and per-
formed on a STACompact coagulation analyzer (Roche
Diagnostics GmbH, Mannheim, Germany).
Assessment of end points. All patients underwent
preoperative and postoperative assessment by an indepen-
dent neurologist. Patients were scored according to the
NIHSS. Patients who had an increase from the preoperative
NIHSS underwent at least one cranial CT scan to assess
morphologic changes of the brain. Transient ischemic at-
tack (TIA) was defined as a neurologic deficit lasting 24
hours, and strokes were defined as central neurologic defi-
cits lasting 24 hours.
statis
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assessed by full blood counts at 4, 24, and 48 hours
postoperatively as well as with tight clinical inspections.
Heparin-induced thrombocytopenia was defined as a de-
crease in platelet count after heparin administration either
by half or 100 109/L.12 Patients who fulfilled these
criteria underwent antibody testing. Severe bleeding was
defined as any postoperative bleeding indicating blood
transfusion or surgical revision. Patients with rapidly grow-
ing swelling or airway compromise at the surgical site, or
both, had emergency revision surgery.
Statistical methods. The study was exploratory in
nature and therefore not powered to demonstrate a partic-
ular treatment effect. Patients were assigned in a 3:1 ran-
domization to receive either enoxaparin (0.5 mg/kg) or
UFH (5000 IU) intraoperatively as an intravenous bolus
(120 and 40 patients, respectively). The 3:1 randomization
strategy was claimed by the local Ethics Committee for this
pilot trial to estimate efficacy and safety of LMWH during
carotid surgery because no relevant data on this question
were available. This randomization mode was agreed upon
with the Ethics Committee because the alternative would
have been a comparison with historical controls. The
planned sample size of 120 patients was sufficient to esti-
mate the stroke rate using a 95% confidence interval (CI)
with a precision of 3.3% if the true event rate was 3.5%.
Consequently, if a stroke rate of 2.2% was observed in this
study (as could be expected from earlier experience at the
study center), the upper boundary of the 95% confidence
interval would be 5.5% and therefore within the range of
pertinent guidelines. The sample size of 40 for the control
group was primarily chosen because of feasibility consider-
ations and would allow for a test power of 80% in case the
difference of stroke rates between groups were as extreme
as 2.2% vs 20.4% at a two-sided 5% significance level.
Randomization was according to an online protocol on the
day of surgery.
Owing to the explorative nature of this study, descrip-
tive summaries were primarily used. The primary efficacy
analysis was based on the full analysis population and esti-
mated the thromboembolic stroke rate30 days of surgery
using a 95% exact CI. The same method was applied for
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aP for age; Mann-Whitney U test for all other parameters; 2 test; P  0.05secondary thromboembolic end points (TIA, prolongedreversible ischemic neurologic deficit) and the overall
thromboembolic event rate. Event rates between treatment
groups were compared with 2 tests. Values of P .05 were
considered significant.
RESULTS
From July 2005 to June 2006, 338 consecutive pa-
tients undergoing carotid endarterectomy at our institution
were screened for this study, of whom 115 patients (34%)
did not fulfill inclusion criteria, and 63 refused to partici-
pate in a clinical trial (19%); thus, 160 of the consecutive
patients (47%) were included. One-third of the 115 ex-
cluded patients represented acute carotids (TIA or stroke
24 hours), and most of the remaining patients were
excluded because of intravenous or catheter-based lysis of
different vascular beds 2 months, were taking dual anti-
platelets, were already being treated with UFH or enoxapa-
rin, or were taking oral anticoagulation. Because the Ethics
Committee and the primary investigator were concerned to
preclude inclusion of patients at excessive risk of mainly
intracerebral bleeding due to the different anticoagulation
effects of enoxaparin so far not addressed in a clinical trial
for carotid surgery, these patients were not included in the
study. A total of 160 patients underwent randomization;
however, surgery was postponed for one woman in the
enoxaparin group because she presented with cardiovascu-
lar symptoms on the day before surgery. Thus, the study
comprised 159 patients, 119 in the enoxaparin group and
40 in the UFH group.
Demographic data and cardiovascular risk factors be-
tween the groups are listed in Table I. Of the included
patients, 106 were men and 53 were women. Their mean
age was 70.3 years (range, 43.3-94.7 years). The difference
in demographic variables between the groups was not
significant.
Table II presents the baseline laboratory values for both
groups. All patients had normal red blood cell and platelet
counts, and global coagulation indicators were within nor-
mal ranges. The serum creatinine level in all patients was
110 mol/L. There was no significant difference in the
laboratory variables between the groups.
Anticoagulation in the UFH group was performed by a
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enoxaparin group received a body weight–adjusted bolus of
enoxaparin of 0.5 mg/kg, representing a mean total dose of
38.0 mg. The Fig shows the anticoagulation effect of both
types of heparins, as estimated by the antifactor Xa activi-
ties. Antifactor Xa levels were measured before and at 15,
30, and 45 minutes after enoxaparin or UFH administra-
tion. Sufficient anticoagulation was obtained with both
enoxaparin and UFH; however, the antifactor Xa levels 15
minutes after the UFH injection were highly variable and
were significantly higher than after enoxaparin 30 and 45
minutes after application.
For the four time points (before and 15, 30 and 45
minutes after) median antifactor Xa levels were 0.10 
0.07, 0.91  0.32, 0.93  0.26, and 0.85  0.20 IU/mL
in the enoxaparin group and 0.12  0.13, 1.28  0.78,
1.37  0.41, and 1.23  0.31 IU/mL in the UFH group.
The statistical differences between the groups for the dif-
ferent time points were P  .8, P  .08, P  .0007, and
P  .0028, respectively. Within groups, there was no
significant difference between time points.
The occurrence of TIA and stroke was 1.3% for the
whole study population (1 patient in the enoxaparin group,
0.8%; 1 patient in the UFH group, 2.5%; P  .4152; Table
III). Two patients in each group needed surgical revision.
One patient in the UFH group had bleeding from the
margin of the skin incision, not compromising breathing or
inducing swelling of the neck, and a single interrupted
suture at bedside was sufficient to stop the bleeding.
The incidence of severe bleeding complications was
2.5% for the whole study population: two patients in the
enoxaparin group (1.7%) and two patients in the UFH
group (5%; P  0.35; Table IV). The body weight–ad-
justed doses of UFH for the three patients with bleeding
complications were 62.5, 71, and 74 IU/kg, respectively.
The antifactor Xa activity 30 minutes after infusion was
0.92, 1.09, and 0.96 U/mL, respectively, and at 4 hours
was 0.71, 0.65, and 0.77 U/mL, respectively. The two
patients with perioperative bleeding complications in the
enoxaparin group had doses of 30 mg and 42 mg enoxapa-
rin with antifactor Xa levels of 1.03 and 0.98 U/mL,
respectively, 30 minutes after enoxaparin administration
Table II. Baseline laboratory values in patients undergoin
Variablea Enoxapari
Red blood cell counts, 1012/L 4.3 (4.0-4.6
Hemoglobin concentration, g/L 132 (126-13
Hematokrit, /L 0.39 (0.37-0
Platelet counts, 109/L 234 (197.5-
Serum creatinine, mol/L 79.6 (70.7-8
Prothrombin time, % 89 (84-94)
APTT 26.0 (24.0/2
APTT, Activated partial thromboplastin time.
aData are presented as median values and interquartile ranges.
bMann-Whitney U test; P  0.05, statistically significant.and 0.67 and 0.5 U/mL at 4 hours.One patient died during follow-up of a myocardial
infarction. After an uneventful postoperative course and
discharge on day 5, she was readmitted on day 22 because
of chest pain caused by an ultimately fatal myocardial
infarction.
None of the patients presented with clinical or labora-
tory signs ofHIT. Two patients in theUFHgroup required
blood transfusions, both of which had a wound revision for
hematoma. Preoperative median platelet counts (109/L)
in the enoxaparin groupwere 234 (IRQ, 197.5-279) and in
the UFH group 210 (IRQ, 195.5-249.5). Postoperative
platelet counts were 199 (IRQ, 179-234) and 199 (177-
233), respectively.
DISCUSSION
Unfractionated heparin is the most widely used heparin
in vascular surgery and endovascular interventions today;
however, evidence is growing that the LMWHs, and
among these enoxaparin, are as effective and in some cases
safer than UFH.2,7 The current study comparing a single
body weight–adjusted bolus of enoxaparin compared with
fixed-doseUFHduring carotid surgery—to our knowledge
the first assessing LMWH in carotid surgery—corroborates
these findings. In this pilot study, enoxaparin had compa-
rable efficacy by means of anticoagulant effects and safety
by means of occurrence of major bleeding complications.
For carotid surgery, local bleeding complication at the
surgical site indicating revision—usually as an emergency
procedure due to airway compromise—is a serious compli-
cation causing considerable morbidity and mortality.










Table III. Outcome end points of patients after carotid
surgery
Variable Enoxaparin Unfractionated heparin Pa
Severe bleeding 1.7% 5% 0.35
Stroke 0.8% 2.5% 0.41
Deaths 0.8% 0% 0.56
TIA, transient ischemic attack.







8.0)safe as a standard dose of UFH in the current study. Severe
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operating room were observed in 1.7% in the enoxaparin
and in 5% in the UFH group; one patient only needed a
single suture due to bleeding from the wound margin,
adding up to 7.5% in the UFH group. These results are in
keeping with results at our institution of 3% and are supe-
rior to the rate of severe bleeding complications in the
literature, which is as high as 10.9%.13
All bleeding complications occurred and were treated
before patients received their first postoperative subcutane-
ous enoxaparin dose. This is of relevance, because mixing
UFH and enoxaparin may cause excessive bleeding compli-
cations. Such an effect has been reported for cardiac bypass
surgery in relatively small sample sizes14 and also for per-
cutaneous coronary revascularization.15 Investigators in
the Superior Yield of the New Strategy of Enoxaparin,
Revascularization and Glycoprotein IIb/IIIa Inhibitors
(SYNERGY) trial concluded that a modest increase of
bleeding was observed when enoxaparin and UFH were
combined; yet, when enoxaparin was used alone, it was
suggested to be superior to UFH.
A fixed dose of 5000 IU of UFH was used in the
current study because this represents a very common prac-
tice in vascular surgery2-5 and has been applied at our
institution for 4000 carotid endarterectomies, with a 3%
rate for surgical revision owing to local bleeding.16 The
comparison of a fixed dose of UFH compared with a body
weight–adjusted dose of LMWH may be a limitation of this
study. One aim of this pilot trial, however, was to find an
anticoagulant regimen that would overcome the somewhat
improvable (although widely used) UFH protocol, which
does not consider individual differences of heparin response
of patients independent of adjusting for body weight. In
fact, the used body weight–adjusted dose of enoxaparin
resulted in antifactor Xa levels in the same range as with
fixed-dose UFH, yet with less variability (Fig).
Nonspecific interactions of heparin with several plasma
proteins also have the potential to limit the amount of
heparin available to bind to antithrombin, rendering its
anticoagulant effect quite unpredictable.17-21 Thus, the
frequently advocated body weight–adjusted heparinization
does not appear to be particularly useful. It is also not clear
which dose is optimal because 70 up to 100 IU/kg are
used.22,23
Most important, for these regimens, antagonization
with protamine was recommended, which is a potential
cause for significant morbidity.24 In this respect, however,
UFH is superior to LMWH because the at least partial
inability to reverse the effect of enoxaparin is frequently
regarded as a serious limitation for its use in vascular
surgery. Yet, protamine does neutralize antithrombin activ-
ities and approximately 60% of antifactor Xa activities in
LMWH.24 This finding is highlighted by the study of
Norgren et al,2 where protamine was used to reverse enox-
aparin effects in patients with excessive intraoperative
bleeding. Also important was that antagonization was used
in the enoxaparin group significantly less than in the UFH
group (3% vs 8%; P  .001). Thus, it appears that antico-agulation at a desired level and duration, in a highly repro-
ducible fashion, requires less frequent reversing. Finally,
pharmacokinetics of enoxaparin given intravenously differs
considerably from its subcutaneous application.25 When
given intravenously, enoxaparin at 0.5 mg/kg reaches a
desired anticoagulation for only up to 2 hours.26
In the current study, the mean body weight–adjusted
dose of UFH was 69.4  12.7 IU/kg for all patients. The
body weight–adjusted doses of heparin for the three pa-
tients with bleeding complications were 62.5, 71, and 74
IU/kg and thus well within the suggested range for opti-
mal anticoagulation.
The dose of 0.5 mg/kg for enoxaparin seems to be
efficient and safe because the stroke rate and bleeding rate
were both comparable with these rates for UFH. The mean
dose in our patient population was 38  5.8 mg, and is thus
comparable to the fixed dosing of 40 mg enoxaparin used
by Norgren et al2 for peripheral vascular surgery. The two
patients with perioperative bleeding complications had re-
ceived doses of 30 mg and 42 mg enoxaparin without a
considerable elevation of the antifactor Xa levels.
Low-molecular-weight heparin exhibits considerably
less nonspecific binding to plasma proteins than UFH,27
and its anticoagulant response, as measured by antifactor
Xa levels, is more predictable than for UFH.26 Thus, body
weight–adjusted dosing does appear to be more useful. All
these effects imply that enoxaparin may be a more reliable
and predictable alternative to UFH; however, comparing
anticoagulation effects for these heparins is difficult. Anti-
factor Xa measurements are not optimal, especially for
monitoring UFH, but in this study, the assay was calibrated
for UFH.
CONCLUSION
Body weight–adjusted enoxaparin seems to be as effec-
tive and safe as UFH during carotid endarterectomy. On
the basis of the results of the current pilot study, more than
Fig. Course of the anticoagulation response before carotid sur-
gery and after an intravenous (iv) bolus of unfractionated heparin
(UNF) or low-molecular-weight heparin (LMWH) at 15, 30 and
45 minutes postoperatively as estimated by antifactor Xa activities
(IU/mL). The solid line, enoxaparin (n  119); dotted line, UNF
(n  40). Median values are presented with interquartile ranges
(whiskers). ***P  .001; **P  .01 Kruskal-Wallis test.800 patients would need to be randomized between the
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AUTHOR CONTRIBUTIONS
Conception and design: AA, PK, AK
Analysis and interpretation: AA, PK, WH, GH
Data collection: AA, CS, NP
Writing the article: AA, PK
Critical revision of the article: AA, PK, WH, CS, AK, NP,
GH
Final approval of the article: AA, PK,WH,CS, AK,NP, GH




1. MurrayDWG.Heparin in surgical treatment of blood vessels. Arch Surg
1940;40:307.
2. Norgren L, for the Swedish EnoxaVasc Study Group. Can low molec-
ular weight heparin replace unfractionated heparin during peripheral
arterial reconstruction? An open label prospective randomized con-
trolled trial. J Vasc Surg 2004;39:977-84.
3. Assadian A, Senekowitsch C, Assadian O, Eidher U, Hagmüller GW,
Knöbl P. Antithrombotic strategies in vascular surgery: evidence and
practice. Eur J Vasc Endovasc Surg 2005;29:516-21.
4. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR,
et al. Beneficial effects of clopidogrel combined with aspirin in reducing
cerebral emboli in patients undergoing carotid endarterectomy. Circu-
lation 2004;109:1476-81.
5. Poisik A, Heyer EJ, Solomon RA, Quest DO, Adams DC, Baldasserini
CM, et al. Safety and efficacy of fixed dose heparin in carotid endarter-
ectomy. Neurosurgery 1999;45:434-41.
6. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WJ.
Heparin kinetics in venous thrombosis and pulmonary embolism. Cir-
culation 1976;53:691-5.
7. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE,
et al; STEEPLE Investigators. Enoxaparin versus unfractionated hepa-
rin in elective percutaneous coronary intervention. N Engl J Med
2006;355:1006-17.
8. North American Symptomatic Carotid Endarterectomy trial Collabora-
tors. Beneficial effect of carotid endarterectomy in symptomatic patients
with high-grade stenosis. N Engl J Med 1991;325:445-53.
9. Sabeti S, Schillinger M, Mlekusch W, Willfort A, Haumer M, Nacht-
mann T, et al. Quantification of internal carotid artery stenosis with
duplex us: comparative analysis of different flow velocity criteria. Radi-
ology 2004;232:431-9.
10. Nicolaides AN, Shifrin EG, Bradbury A, Dhanjil S, Griffin M, Belcaro
G, Williams M. Angiographic and duplex grading of internal carotid
stenosis: can we overcome the confusion? J Endovasc Surg 1996;3:
158-65.
11. Young FB, Weir CJ, Lees KR, GAIN International Trial Steering
Committee and Investigators. Comparison of the National Institutes of
Health Stroke Scale with disability outcome measures in acute stroke
trials. Stroke 2005;36:2187-92.12. Warketin TE. An overview of the heparin induced thrombocytopenia
syndrome. Semin Thromb Hemost 2004;30:273-83.
13. Forsell C, Takolander R, Bergquist D, Johansson A, Person NH. Local
versus general anaesthesia in carotid surgery. A prospective randomized
study. Eur J Vasc Surg 1989;3:503-9.
14. Jones HU, Huhlenstein JB, Jones KW, Bair TL, Lavasani F, Shrevardi
M, et al. Preoperative use of enoxaparin compared with unfractionated
heparin increases the incidence of re-exploration for postoperative
bleeding after open-heart surgery in patients who present with an acute
coronary syndrome: clinical investigation and reports. Circulation
2002;106(12 suppl 1):I19-22.
15. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS,
Chiswell K, et al. Efficacy and safety of enoxaparin compared with
unfractionated heparin in high-risk patients with non-ST-segment ele-
vation acute coronary syndrome undergoing percutaneous coronary
intervention in the Superior Yield of the New Strategy of Enoxaparin,
Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY)
trial. Am Heart J 2006;152:1042-50.
16. Assadian A, Senekowitsch C, AssadianO, PtakovskyH,Hagmüller GW.
Perioperative morbidity and mortality of carotid artery surgery under
loco-regional anaesthesia. VASA 2005;34:41-5.
17. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutraliza-
tion of heparin-related saccharides by histidine-rich glycoprotein and
platelet factor 4. J Biol Chem 1986;261:3980-6.
18. Rucinsky B, Niewiaroski S, Strzyzewski M, Holt JC,Mayo KH.Human
platelet factor 4 and its C-terminal peptides: heparin binding and
clearance from the circulation. Thromb Haemost 1990;63:493-8.
19. Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of
human histidine-rich glycoprotein: mechanism and role in the neutral-
ization of heparin in plasma. J Biol Chem 1983;258:3803-8.
20. Preissner KT, Muller-Berghaus G. Neutralization and binding of hep-
arin by S-protein/vitronectin in the inhibition of factor Xa by anti-
thrombin III. J Biol Chem 1987;262:12247-53.
21. A, Pepper DS, Dawes J. Interaction of immobilised unfractionated and
LMW heparins with proteins in whole human plasma. Thromb Hae-
most 1993;70:951-8.
22. Self DD, BrysonGL, Sullivan PJ. Risk factors for post-carotid endarter-
ectomy hematoma formation. Can J Anaesth 1999;46:635-40.
23. Coyne TJ, Wallace MC, Benedict C. Peri-operative anticoagulant ef-
fects of heparinization for carotid endarterectomy. Aust N Z J Surg
1994;64:679-83.
24. Hirsh J, Raschkr R. Heparin and low-molecular-weight heparin: the
Seventh ACCP Conference on Antithrombotic and Thrombolytic
Therapy. Chest 2004;126(3 suppl):188S-203S.
25. Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacoki-
netics of intravenous/subcutaneous enoxaparin in patients with acute
coronary syndrome undergoing percutaneous coronary interventions.
Catheter Cardiovasc Interv 2002;57:187-90.
26. Sanchez-Pena P, Hulot JS, Urien S, Ankari A, Collet JP, Choussat R, et
al. Anti-factor Xa kinetics after intravenous enoxaparin in patients
undergoing percutaneous coronary intervention: a population model
analysis. Br J Clin Pharmacol 2005;60:364-73.
27. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in vitro
evidence that low molecular weight heparins exhibit less binding to
plasma proteins than unfractionated heparin. Thromb Haemost 1994;
71:300-4.Submitted Jul 16, 2007; accepted Oct 27, 2007.
